{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T07:18:11Z","timestamp":1791357491234,"version":"4.3.1"},"reference-count":53,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2022,2,22]],"date-time":"2022-02-22T00:00:00Z","timestamp":1645488000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["movementdisorders.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Movement Disorders"],"published-print":{"date-parts":[[2022,4]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:p>Vesicular monoamine transporter type 2 (VMAT2) inhibitors may be an effective therapy for chronic tic disorders (CTD), including Tourette syndrome (TS), but there has not been a meta\u2010analysis compiling available evidence from randomized controlled trials (RCTs). We performed a systematic review and meta\u2010analysis to evaluate the efficacy, acceptability, and tolerability of VMAT2 inhibitors for CTD\/TS. PubMed, CENTRAL, and Embase were searched for double\u2010blinded RCTs of VMAT2 inhibitors versus placebo for the treatment of CTD\/TS. Change in tic severity measured by the Yale Global Tic Severity Scale (efficacy) and rates of discontinuation attributed to adverse effects (tolerability) or all causes (acceptability) were extracted closest to 12\u2009weeks. Mean difference (MD) and odds ratio (OR) were the effect size indexes for efficacy and acceptability\/tolerability, respectively. Data were pooled through random\u2010effects meta\u2010analysis weighted by inverse variance. Five RCTs involving eight comparisons were included. Meta\u2010analysis found a nonsignificant effect on efficacy (<jats:italic>k<\/jats:italic>\u00a0=\u00a08; N\u00a0=\u00a0583; MD\u00a0=\u00a0\u22120.71; 95% confidence interval [CI], \u22121.93 to 0.50; <jats:italic>P<\/jats:italic>\u00a0=\u00a00.24), and there was certainty that the true effect is nonclinically meaningful (high quality of evidence). Meta\u2010analysis found decreased tolerability (<jats:italic>k<\/jats:italic>\u00a0=\u00a07; N\u00a0=\u00a0626; OR\u00a0=\u00a02.67; 95% CI, 1.21\u20135.92; <jats:italic>P<\/jats:italic>\u00a0=\u00a00.01) and decreased acceptability (<jats:italic>k<\/jats:italic>\u00a0=\u00a08; N\u00a0=\u00a0626; OR\u00a0=\u00a01.90; 95% CI, 1.14\u20133.18; <jats:italic>P<\/jats:italic>\u00a0=\u00a00.01), although those comparisons were limited because of the relatively small number of events across trials. Meta\u2010analyses did not support the efficacy of VMAT2 inhibitors in the short\u2010term treatment of tic disorders and suggested no clinically meaningful effect of these agents on tic symptoms. \u00a9 2022 International Parkinson and Movement Disorder Society<\/jats:p>","DOI":"10.1002\/mds.28957","type":"journal-article","created":{"date-parts":[[2022,2,22]],"date-time":"2022-02-22T08:23:26Z","timestamp":1645518206000},"page":"684-693","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["<scp>Meta\u2010Analysis<\/scp>: Efficacy and Tolerability of Vesicular Monoamine Transporter Type 2 Inhibitors in the Treatment of Tic Disorders"],"prefix":"10.1002","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6060-447X","authenticated-orcid":false,"given":"Emily","family":"Behling","sequence":"first","affiliation":[{"name":"Yale Child Study Center, Yale School of Medicine  New Haven Connecticut USA"},{"name":"University of Connecticut School of Medicine University of Connecticut Health Center  Farmington Connecticut USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3147-8344","authenticated-orcid":false,"given":"Luis C.","family":"Farhat","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Faculdade de Medicina FMUSP Universidade de S\u00e3o Paulo  S\u00e3o Paulo Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9556-6132","authenticated-orcid":false,"given":"Angeli","family":"Landeros\u2010Weisenberger","sequence":"additional","affiliation":[{"name":"Yale Child Study Center, Yale School of Medicine  New Haven Connecticut USA"},{"name":"Department of Psychiatry Yale School of Medicine  New Haven Connecticut USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0352-4080","authenticated-orcid":false,"given":"Michael H.","family":"Bloch","sequence":"additional","affiliation":[{"name":"Yale Child Study Center, Yale School of Medicine  New Haven Connecticut USA"},{"name":"Department of Psychiatry Yale School of Medicine  New Haven Connecticut USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2022,2,22]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2016.97"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jocrd.2014.06.002"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.26089"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpsychores.2009.09.002"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.23199"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpsychires.2013.12.009"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neubiorev.2012.09.008"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000007466"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)31135-3"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2009.1549"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaac.2013.09.015"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00787-011-0163-7"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2018.02.1172"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000198586.85250.13"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2016.8655"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S133205"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.19r12798"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1080\/14737175.2018.1500178"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1080\/14656566.2016.1258063"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1177\/0883073807307108"},{"key":"e_1_2_8_22_1","volume-title":"Xenazine (tetrabenazine) tablets [prescribing information]","year":"2013"},{"key":"e_1_2_8_23_1","volume-title":"Austedo (deutetrabenazine) tablets [prescribing information]","year":"2017"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000005817"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.3233\/JHD-130071"},{"key":"e_1_2_8_26_1","first-page":"9","article-title":"Tetrabenazine in the treatment of Tourette syndrome","volume":"5","author":"Kenney C","year":"2007","journal-title":"J Ped Neurol"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.5334\/tohm.287"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.34.5.688"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.2165\/00044011-200828070-00006"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.28204"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.29397"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71"},{"key":"e_1_2_8_33_1","doi-asserted-by":"publisher","DOI":"10.1080\/14737175.2021.1898948"},{"key":"e_1_2_8_34_1","doi-asserted-by":"publisher","DOI":"10.1097\/00004583-198907000-00015"},{"key":"e_1_2_8_35_1","first-page":"550","volume-title":"Tourette's Syndrome and Tic Disorders","author":"Leckman JF","year":"1988"},{"key":"e_1_2_8_36_1","volume-title":"ECDEU Assessment and Manual for Psychopharmacology","author":"Guy W","year":"1976"},{"key":"e_1_2_8_37_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898"},{"key":"e_1_2_8_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2010.04.026"},{"key":"e_1_2_8_39_1","doi-asserted-by":"publisher","DOI":"10.1002\/jrsm.1259"},{"key":"e_1_2_8_40_1","doi-asserted-by":"publisher","DOI":"10.1136\/eb-2018-102911"},{"key":"e_1_2_8_41_1","doi-asserted-by":"publisher","DOI":"10.1136\/ebmental-2019-300117"},{"key":"e_1_2_8_42_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000005474"},{"key":"e_1_2_8_43_1","doi-asserted-by":"publisher","DOI":"10.1037\/1040-3590.17.4.486"},{"key":"e_1_2_8_44_1","doi-asserted-by":"publisher","DOI":"10.1017\/S2045796021000664"},{"key":"e_1_2_8_45_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2377-9-62"},{"key":"e_1_2_8_46_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2014.2650"},{"key":"e_1_2_8_47_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neubiorev.2012.11.013"},{"key":"e_1_2_8_48_1","doi-asserted-by":"publisher","DOI":"10.1089\/cap.2010.0149"},{"key":"e_1_2_8_49_1","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2021.626459"},{"key":"e_1_2_8_50_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.26891"},{"key":"e_1_2_8_51_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.12m08189"},{"key":"e_1_2_8_52_1","doi-asserted-by":"publisher","DOI":"10.1089\/cap.2016.0026"},{"key":"e_1_2_8_53_1","doi-asserted-by":"publisher","DOI":"10.1212\/01.WNL.0000055434.39968.67"},{"key":"e_1_2_8_54_1","doi-asserted-by":"publisher","DOI":"10.1097\/WNF.0000000000000326"}],"container-title":["Movement Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/mds.28957","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/mds.28957","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/movementdisorders.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/mds.28957","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T09:58:27Z","timestamp":1760954307000},"score":1,"resource":{"primary":{"URL":"https:\/\/movementdisorders.onlinelibrary.wiley.com\/doi\/10.1002\/mds.28957"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,22]]},"references-count":53,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["10.1002\/mds.28957"],"URL":"https:\/\/doi.org\/10.1002\/mds.28957","archive":["Portico"],"relation":{},"ISSN":["0885-3185","1531-8257"],"issn-type":[{"value":"0885-3185","type":"print"},{"value":"1531-8257","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,22]]},"assertion":[{"value":"2021-11-23","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-01-24","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-02-22","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}